MedTrace Logo

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

NCT03562533 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 432

Last updated 2019-02-28

No results posted yet for this study

Summary

This retrospective multicenter study aimed to evaluate the effectiveness of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with carboplatin and paclitaxel (CP) in patients who had disease progression longer than 6 months after first-line platinum+taxane chemotherapy for ovarian cancer in real world clinical practice.

Conditions

  • Ovarian Carcinoma

Interventions

DRUG

pegylated liposomal doxorubicin (PLD) + carboplatin (CD)

carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles

DRUG

carboplatin + paclitaxel (CP)

carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • National Cancer Center, Korea

    collaborator OTHER_GOV

  • Asan Medical Center

    collaborator OTHER

  • The Catholic University of Korea

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Chung-Ang University Hosptial, Chung-Ang University College of Medicine

    collaborator OTHER

  • Ajou University

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Konkuk University Medical Center

    lead OTHER

Principal Investigators

  • Seung Hyuk Shim, MD · Konkuk University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-17
Primary Completion
2018-12-17
Completion
2018-12-17
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03562533 on ClinicalTrials.gov